载金纳米粒持续释放抗白血病药物：通过质量源于设计方法进行开发、优化和评价。
Gold nanoparticles for sustained antileukemia drug release: development, optimization and evaluation by quality-by-design approach.
机构信息
Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, India.
出版信息
Nanomedicine (Lond). 2019 Apr;14(7):851-870. doi: 10.2217/nnm-2018-0306. Epub 2019 Mar 22.
AIM
To design, develop, optimize and evaluate sustained-release dasatinib-loaded gold nanoparticles (DSB-GNPs) to treat chronic myeloid leukemia (CML) by using quality by design.
MATERIALS & METHODS: In this study, we performed risk assessment, optimization, in vitro characterizations, stability study, drug release studies, cytotoxicity study and in vivo pharmacokinetic evaluation.
RESULTS
DSB-GNPs of desired size, entrapment, smooth, spherical, stable and sustained drug release for 48 h were achieved. DSB-GNPs exhibited significantly more percentage growth inhibition and enhanced systemic bioavailability compared with pure DSB.
CONCLUSION
The in vitro and in vivo evaluation exhibited that the DSB-GNPs have a potential cytotoxic effect, systemic bioavailability and sustained release making them a promising system of DSB delivery in the treatment of chronic myeloid leukemia.
目的
通过质量源于设计，设计、开发、优化和评估载有达沙替尼的金纳米粒（DSB-GNPs），以治疗慢性髓性白血病（CML）。
材料与方法
在这项研究中，我们进行了风险评估、优化、体外特性、稳定性研究、药物释放研究、细胞毒性研究和体内药代动力学评价。
结果
得到了具有所需粒径、包封率、光滑、球形、稳定和 48 小时持续药物释放的 DSB-GNPs。与纯 DSB 相比，DSB-GNPs 显示出更高的百分比生长抑制和增强的系统生物利用度。
结论
体外和体内评价表明，DSB-GNPs 具有潜在的细胞毒性作用、系统生物利用度和持续释放，使它们成为治疗慢性髓性白血病的 DSB 递药系统的一种有前途的选择。
Zotero 插件